Daniel R Ganger

Grants

Grants per year 2005 2010 2011 2012 2013 2025

• 6 Active
• 43 Finished

Grants per year

Search results

• Finished

  Prot#RNHE2041: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

  Ganger, D. R. & Flamm, S. L.

  TMC Pharma Services Ltd., Salix Pharmaceuticals, Inc.

  9/17/18 → 9/17/22

  Project: Research project

• Frailty and Functional Status in Older Liver Transplant Patients

  Ladner, D. P. & Ganger, D. R.

  University of California, San Francisco, National Institute on Aging

  9/15/18 → 8/31/19

  Project: Research project

  • Transplantation 100%
  • Patient 100%
  • Functional Status 66%
  • Enalapril Maleate 50%
  • Mortality 50%

• Prot# M16-135: A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

  Ganger, D. R. & Flamm, S. L.

  AbbVie Inc.

  9/8/17 → 9/7/20

  Project: Research project

• Prot# MNK19013058: A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects with Hepatorenal Syndrome Type 1

  Ganger, D. R.

  International HealthCare, LLC, Mallinckrodt Hospital Products Inc.

  6/15/16 → 6/15/21

  Project: Research project

• Acute Liver Failure Study Group 13C-Methacetin Breath Test for the Prediction of Outcome in Acute Liver Failure

  Ganger, D. R.

  University of Texas Southwestern Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases

  2/19/16 → 8/31/20

  Project: Research project

  • breath 100%
  • patients 75%
  • liver 75%
  • failures 75%
  • carbon 13 75%

• A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) -- A Multi-Center Group to Study Acute Liver Failure

  Ganger, D. R.

  University of Texas Southwestern Medical School, National Institute of Diabetes and Digestive and Kidney Diseases

  9/18/15 → 8/31/19

  Project: Research project

  • liver 100%
  • patients 80%
  • failures 80%
  • Acute Liver Failure 80%
  • safety 70%

• Prot #MK-3682-012-01: A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection.

  Ganger, D. R.

  Merck Sharp & Dohme Corporation

  8/5/15 → 8/5/18

  Project: Research project

• Prot # 052-00: A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Disease

  Ganger, D. R.

  Merck Sharp & Dohme Corporation

  3/4/14 → 3/4/17

  Project: Research project

• Prot # ROF-NASH_205: A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects with Nonalcoholic Steatohepatitis

  Rinella, M. E., Ganger, D. R., Green, R., Koppe, S. W. P. & Kulik, L. M.

  Quintiles, Inc., Takeda Development Center Americas, Inc.

  2/11/14 → 2/11/17

  Project: Research project

• Prot # OCR002-HE209: Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with an Episode of Hepatic Encephalopa

  Ganger, D. R.

  Ocera Therapeutics, Inc

  11/8/13 → 11/8/18

  Project: Research project

• Prot# 017-00: A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial

  Ganger, D. R. & Flamm, S. L.

  Merck Sharp & Dohme Corporation

  3/18/13 → 3/31/21

  Project: Research project

• RFHE4043: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rifaximin 550 mg in Subjects with Severe Hepatic Impairment and Overt Hepatic Encephalopathy

  Ganger, D. R. & Levitsky, J.

  Valeant Pharmaceuticals North America LLC, Salix Pharmaceuticals, Inc.

  3/12/13 → 12/31/15

  Project: Research project

• Protocol # 038-00: A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 when Administered Concomitantly with Peginterferon alfa-2b and Rabavirin in Treatment Naive Subjects wi

  Flamm, S. L. & Ganger, D. R.

  Merck Sharp & Dohme Corporation

  1/24/13 → 1/24/16

  Project: Research project

• Prot # GS-US-337-0109: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV I

  Flamm, S. L. & Ganger, D. R.

  PRA Health Sciences, Gilead Sciences, Inc.

  1/4/13 → 1/4/17

  Project: Research project

• Prot # M11-646: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavarin (RBV) in Treatment-Naive Adults with Genotype 1 Chronic He

  Flamm, S. L. & Ganger, D. R.

  AbbVie Inc.

  11/29/12 → 11/29/15

  Project: Research project

• Prot # GS-US-337-0102: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination ± Ribavarin for 12 and 24 Weeks in Treatment-Naive Subjects with Chronic Genotype 1 HCV Infecti

  Flamm, S. L. & Ganger, D. R.

  PRA Health Sciences, Gilead Sciences, Inc.

  10/5/12 → 10/5/15

  Project: Research project

• Adduct Dipstick for Diagnosis of Acetaminophen Toxicity

  Ganger, D. R.

  Arkansas Children's Hospital Research Institute, National Institute of Diabetes and Digestive and Kidney Diseases

  7/1/12 → 6/30/15

  Project: Research project

  • Patient 100%
  • patients 50%
  • liver 40%
  • Diagnosis 40%
  • adducts 30%

• Prot # 003-23: A Phase II Randomized, Partially Blinded, Pilot Study to Evaluate the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Treatment-Naive (TN) Patients with Chronic Genotype 1 (GT 1) Hepatitis C Virus Infection" MK-5172-03

  Flamm, S. L. & Ganger, D. R.

  Merck Sharp & Dohme Corporation

  6/1/12 → 6/1/13

  Project: Research project

• Prot # AI444052: A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C

  Flamm, S. L. & Ganger, D. R.

  Bristol-Myers Squibb Company

  5/9/12 → 5/9/15

  Project: Research project

• Prot# GX-US-174-0172: Prospective, Observational, Post-marketing Renal Safety Surveillance Registry in Patients with Chronic Hepatitis B (HBV) Infection with Decompensated Liver Disease Receiving Nucleotide/side Therapy While on the Orthotopic Liver Trans

  Ganger, D. R. & Flamm, S. L.

  PRA Health Sciences, Gilead Sciences, Inc.

  3/19/12 → 3/19/18

  Project: Research project

• Prot# VX11-222-106: A Multicenter, Randomized, Double-blind, Placebo- Controlled, Phase 2b Study to Compare the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, Ribavirin) to Triple Therapy (with VX-222-Placebo) in Subje

  Flamm, S. L. & Ganger, D. R.

  Parexel, Vertex Pharmaceuticals Incorporated

  3/15/12 → 3/15/16

  Project: Research project

• Prot # VX11-950-114: A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype

  Flamm, S. L. & Ganger, D. R.

  Parexel, Vertex Pharmaceuticals Incorporated

  3/8/12 → 3/8/16

  Project: Research project

• Prot# VX11-950-116: An Open-Label, Phase 4 study of Telaprevir, Peginterferon Alfa-2a(Pegasys), and Ribavirin(Copegus) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not

  Flamm, S. L. & Ganger, D. R.

  Parexel, Vertex Pharmaceuticals Incorporated

  3/8/12 → 3/8/16

  Project: Research project

• Protocol TMC435HPC2002:An exploratory Phase IIa, randomized, open-label trial to investigate the efficacy and safety of 12 weeks or 24 weeks of TMC435 in combination with PSI-7977 with or without ribavirin in chronic hepatitis C genotype 1-infected prior

  Flamm, S. L. & Ganger, D. R.

  Tibotec Pharmaceuticals Ltd.

  1/26/12 → 6/4/14

  Project: Research project

• Prot # CDEB025A2301: A Randomized, Double-blind, Placebo-Controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination with Standard of Care in Hepatitis C Genotype 1 Treatment-nave Patients

  Flamm, S. L. & Ganger, D. R.

  Novartis Pharmaceuticals Corporation

  9/19/11 → 9/19/14

  Project: Research project